Arphamid develops therapeutics that keep cancer patients on life-saving treatment. We target debilitating complications that force patients to reduce or stop chemotherapy. Dimiracetam, a glutamate modulator (Phase 2-ready), prevents early symptoms of oxaliplatin neuropathy. RF4662 reduces breakthrough pain episodes via GPR103 antagonism (IND-ready). RF4442 addresses cachexia via GPR10 antagonism. We seek €25M to advance three value-inflection milestones toward a €3.5B market.

Tuesday, May 5, 13:45 - 15:00, room Singapore

Cube Biotech specializes in solving complex problems in protein research, with a specific emphasis on the challenging class of membrane proteins. We take pride in covering all stages of protein preparation utilizing our NativeMP copolymer stabilization platform, protein purification capabilities, biophysical target characterization applications, and structure determination via cryo-EM or crystallography.

Effective topical treatment of the esophagus is difficult due to the ultra-short transit time of only seconds from mouth to stomach. EsoCap has developed a versatile drug delivery platform that enables efficient, localized administration of small molecules, antibodies, and RNA-based therapies. The technology supports improved treatment of EoE, reflux disease, esophageal cancer, and other gastrointestinal disorders by enhancing mucosal contact and therapeutic precision.

HDI Global offers a wide range of insurance solutions for startups, medium-sized businesses, large companies, and international corporate groups. As a partner in transformation, HDI combines local expertise with a global network, providing worldwide coverage and innovative solutions for new technologies and risks. For life sciences, HDI offers specialised cover - such as product liability, recall costs, R&D protection, clinical trials, logistics, and cyber insurance.

Our mission is to unlock the potential of life science innovation no matter where it originates. Johnson & Johnson teams aim to solve the world’s toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere. We know that a great idea can come from anywhere and we are proud of our strong track record of cultivating innovation and pairing our deep internal know-how with some of the most promising external innovation worldwide.

KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. KBI works closely to personalize and rapidly accelerate drug development programs.

MTx develops therapeutic antibodies for viral infections and cancer. Its proprietary DROPZYLLA® technology enables comprehensive screening of human antibody repertoires in recombinant form. Lead asset potravitug targets BK virus in kidney transplant recipients; Phase II data support a Phase III start in 2026. DROPZYLLA® also underpins MTx’s recombinant polyclonal IgG technology and the discovery of tumor-reactive antibodies from tumor-infiltrating B cells.

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Learn more at www.msdlicensing.com.

Oculis is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet needs. Oculis’ late-stage pipeline includes OCS-01, a topical eye drop for DME; Privosegtor, a neuroprotective candidate for optic neuritis and NAION; and Licaminlimab, a topical anti-TNFα for DED. Headquartered in Switzerland, Oculis is led by an experienced management team and is supported by leading healthcare investors.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical need. Santhera holds an exclusive worldwide license from ReveraGen to AGAMREE® (vamorolone), a dissociative steroid investigated in DMD as an alternative to corticosteroids. AGAMREE is approved for DMD in the U.S., EU, UK, China, Hong Kong, and Canada.

Ultimate Medicine (UM) is a Swiss preclinical biotech focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias. The company is pioneering a class of small molecules targeting elevated levels of a novel toxic metabolite that disrupts critical neuronal functions and accelerates disease progression. The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis.

Monday, May 4, 16:00 - 16:15, room Singapore

Vetter is a global leading (CDMO), headquartered in Germany, with production facilities in Germany, Austria, and the US. The company has extensive experience supporting biotechnology and pharmaceutical customers of all sizes. It guides partners through key steps, decisions, and transitions across the development cycle, from preclinical stages to Phase 3. Vetter supports injectable product candidates across a broad range of therapeutic applications and substance classes.